Technology | July 08, 2015

Masimo Receives CE Mark for MightySat Rx Pulse Oximeter

Wireless fingertip pulse oximeter enables clinicians to track and trend measurements through smart mobile devices

Masimo, MightySat Rx, fingertip pulse oximeter, SpO2, pulse rate

July 8, 2015 - Masimo announced the CE Mark and full market release of MightySat Rx fingertip pulse oximeter for clinical use in CE countries. The device uses Masimo's SET Measure-Through Motion and Low Perfusion pulse oximetry.

Bluetooth-enabled versions of MightySat Rx allow clinicians to track and trend up to 12 hours of patient measurements on smart mobile devices, and to share that data via standard CSV files as well as transfer to Apple's Health app.

MightySat Rx enables accurate noninvasive spot-checking of oxygen saturation (SpO2) and pulse rate (PR) for adult and pediatric patients even during motion and low perfusion. The device measures and displays perfusion index (PI), which reflects the strength of the pulsatile signal. MightySat can also measure and display Pleth Variability Index (PVI), a measure of the dynamic changes in the perfusion index that occur during one or more complete respiratory cycle/s.

MightySat Rx is available in three versions for patients who weigh more than 30 kg (66 lbs):

  • MightySat Rx – Measures and displays SpO2, PR, and PI;
  • MightySat Rx, Bluetooth – Adds Bluetooth LE radio for transfer of parameter data to Apple iOS and select Android mobile devices;
  • MightySat Rx, Bluetooth and PVI.

 

Standard features include:

  • Measure-Through Motion and Low Perfusion performance;
  • Signal I.Q. to assess measurement confidence;
  • Rugged, lightweight design for operation in challenging environments;
  • Long battery life – up to 15 hours with two standard AAA alkaline batteries; and
  • Comfortable design with silicon finger pad to mold to patients' fingers.

 

For more information: www.masimo.com

Related Content

World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...
Insomnia Tied to Higher Risk of Heart Disease and Stroke

Image courtesy of the American Heart Association

News | Cardiac Diagnostics | August 19, 2019
People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke,...
Evolutionary Gene Loss May Help Explain Human Predisposition to Heart Attacks
News | Cardiac Diagnostics | July 29, 2019
The loss of a single gene two to three million years ago in our ancestors may have resulted in a heightened risk of...
U.S. Soldiers Have Worse Heart Health Than Civilians
News | Cardiac Diagnostics | June 06, 2019
Active duty Army personnel have worse cardiovascular health compared to people of similar ages in the civilian...
Late Dinner and No Breakfast Worsens Outcomes After Heart Attack
News | Cardiac Diagnostics | May 23, 2019
People who skip breakfast and eat dinner near bedtime have worse outcomes after a heart attack, according to research...
HRS Releases New Expert Consensus Statement on Arrhythmogenic Cardiomyopathy
News | Cardiac Diagnostics | May 14, 2019
The Heart Rhythm Society (HRS) released a first-of-its-kind consensus statement with guidance on the evaluation and...
New Best Practices Help Manage Heart Attack Patients Without Significant Signs
News | Cardiac Diagnostics | April 15, 2019
For the first time in the United States, doctors with the American Heart Association (AHA) have outlined best practices...
The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes.

The most recent U.S. Food and Drug Administration (FDA) clearance was Siemens Healthineers high-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. The test helps in the early diagnosis of myocardial infarctions without the need for serial tropic testing. The time to first results is 10 minutes. 

Feature | Cardiac Diagnostics | March 22, 2019 | Linda C. Rogers, Ph.D.
Troponins are a family of proteins found in skeletal and heart (cardiac) muscle fibers that produce muscular contract
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a heart healthy...
Overlay Init